← All Quidelortho CORP filings

Quidelortho CORP 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
QDEL
Quidelortho CORP
10-Q: QuidelOrtho Reports Q3 Loss Amid Goodwill Impairment, Restructuring
QuidelOrtho Corporation reported a significant net loss in the third quarter of 2025, primarily driven by a $700.7 million goodwill impairment charge and ongoing restructuring efforts.
NASDAQ
QDEL
Quidelortho CORP
10-Q: QuidelOrtho Reports Q2 Loss Amid Restructuring & Revenue Decline
QuidelOrtho Corporation reported a significant net loss in Q2 2025, driven by restructuring charges and a decline in total revenues, despite some growth in core business units.
NASDAQ
QDEL
Quidelortho CORP
10-Q: QuidelOrtho Reports Q1 2025 Results: Revenue Declines Slightly Amidst Strategic Shifts
QuidelOrtho's Q1 2025 revenue decreased by 3% year-over-year to $692.8 million, impacted by U.S. donor screening wind-down and fluctuating respiratory product demand.
NASDAQ
QDEL
Quidelortho CORP
10-Q: QuidelOrtho Reports Net Loss of $1.87 Billion in Q3 2024 Amidst Goodwill Impairment
QuidelOrtho Corporation reported a significant net loss of $1.87 billion for the third quarter of 2024, primarily due to a substantial goodwill impairment charge.
NASDAQ
QDEL
Quidelortho CORP
10-Q: QuidelOrtho Reports Significant Goodwill Impairment and Declining Revenue in Q2 2024
QuidelOrtho's Q2 2024 results reveal a substantial goodwill impairment charge and a decrease in revenue compared to the previous year.
NASDAQ
QDEL
Quidelortho CORP
10-Q: QuidelOrtho Reports $1.7 Billion Goodwill Impairment Charge in Q1 2024 Amidst Revenue Decline
QuidelOrtho Corporation reported a significant net loss of $1.7 billion for the first quarter of 2024, primarily due to a substantial goodwill impairment charge.